Loading
A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, withdrawn before enrolling.
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT is a phase 1 interventional study registered as NCT02786485 by Bellicum Pharmaceuticals, started 2016-05. Conditions recorded: Leukemia, Myelodysplastic Syndromes, Lymphomas, Multiple Myeloma and Other High-risk Hematological Malignancies. Interventions recorded: rivogenlecleucel and Rimiducid.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Leukaemia (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/